Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MG-K10 in Healthy Adults
NCT06277284Phase 1Unknown
- Sponsor
- Hunan Mabgeek Biotechnology
- Start
- Oct 2023
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of comekibart in atopic dermatitis (AD) and asthma (2 arms), sponsored by Hunan Mabgeek Biotechnology. Primary endpoints: Maximum Concentration at 57 days, Area Under the Curve from time 0 to t at 57 days and 1 more. Status: unknown.
02
Drugs
comekibart
03
Conditions
atopic dermatitis (AD)asthma
Beyond the preview
Go deeper on NCT06277284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277284.